Skip to main content

Advertisement

SpringerLink
Log in

Proton Pump Inhibitors and Risk of Bone Fractures

  • Stomach (C Howden, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion Statement

There are 34 studies in almost 2 million participants that have reported on the association between proton pump inhibitor (PPI) therapy and risk of fracture. There is substantial variation between the results of each study but systematic reviews of the data suggest overall there is an association between PPI therapy and risk of fracture. The magnitude of the association is modest and is most likely due to confounding factors as patients prescribed PPI therapy tend to be more frail with more risk factors for fractures than those not given these drugs. There is no clear dose–response relationship and there is no association between PPI therapy and risk of fracture in those at highest risk. Finally, there is no clear mechanism through which PPI therapy increases the risk of fracture, as recent randomized trials show no impact of PPI therapy on calcium absorption and there is no association between PPI therapy and risk of osteoporosis. We therefore feel there is insufficient evidence to change PPI prescribing habits based on risk of fracture. Similarly, we do not recommend bone mineral density investigations for patients taking PPI therapy other than would be normally indicated. There is no evidence to support prescription of calcium and/or vitamin D in patients simply because they are taking PPI therapy. As with all medications, we only recommend prescribing PPI therapy when there is a clear indication that benefit will outweigh risk and at the lowest effective dose. Patients should be regularly assessed as to whether acid suppression is still required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.

    Article  PubMed  Google Scholar 

  2. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009. PLoS ONE. 2013;8(2):e56060.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:912–4.

    Article  Google Scholar 

  4. Sheikh I, Waghray A, Waghray N, Dong C, Wolfe MM. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109:789–94.

    Article  PubMed  Google Scholar 

  5. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9:132–9. Good overview of the evidence that supports all the main serious adverse events that have been associated with proton pump inhibitors. Gives a detailed account of how some of these associations may be explained by confounding factors.

    Article  PubMed  CAS  Google Scholar 

  6. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108:1794–801.

    Article  PubMed  Google Scholar 

  7. Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol. 2012;107:1020–1.

  8. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107:1001–10.

    Article  PubMed  CAS  Google Scholar 

  9. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107:1011–9.

    Article  PubMed  CAS  Google Scholar 

  10. FDA. http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm. Accessed 21st August 2014.

  11. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83.

    Article  PubMed  CAS  Google Scholar 

  12. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.

    Article  PubMed  CAS  Google Scholar 

  13. Moayyedi P, Cranney A. Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm. Am J Gastroenterol. 2008;103:2428–31.

    Article  PubMed  CAS  Google Scholar 

  14. Moayyedi P, CAG Clinical Affairs Committee. Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol. 2008;22:855–8.

    PubMed  PubMed Central  Google Scholar 

  15. Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794–800.

    Article  PubMed  CAS  Google Scholar 

  16. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519–26.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9:25–67.

    Article  Google Scholar 

  18. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18.

    Article  PubMed  CAS  Google Scholar 

  19. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768–76.

    Article  PubMed  CAS  Google Scholar 

  20. Moayyedi P, Yuan Y, Leontiadis G. CAG Clinical Affairs. Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update. Can J Gastroenterol. 2013;27:593–5. The latest systematic review of the association between proton pump inhibitor therapy and risk of fracture. Outlines the evidence for a causal association between fracture and acid suppression.

    PubMed  PubMed Central  Google Scholar 

  21. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–26.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951–9.

    Article  PubMed  CAS  Google Scholar 

  23. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93–101.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2010;19:1131–6.

    Article  PubMed  Google Scholar 

  25. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57:205–10.

    Article  PubMed  Google Scholar 

  26. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case–control study. Osteoporos Int. 2011;22:903–10.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Turner MR, Camacho X, Fischer HD, Austin PC, Anderson GM, Rochon PA, et al. Levothyroxine dose and risk of fractures in older adults: nested case–control study. BMJ. 2011;342(7805):d2238.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case–control analysis in a health-insured population. AIDS. 2012;26:1073–82.

    Article  PubMed  CAS  Google Scholar 

  29. Mazziotti G, Baracca M, Doga M, Porcelli T, Vescovi PP, Giustina A. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur J Endocrinol. 2012;167:865–72.

    Article  PubMed  CAS  Google Scholar 

  30. Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone. 2013;52:557–61.

    Article  PubMed  CAS  Google Scholar 

  31. Chiang CH, Liu CJ, Chen PJ, Huang CC, Hsu CY, Chen ZY, et al. Hip fracture and risk of acute myocardial infarction: a nationwide study. J Bone Miner Res. 2013;28:404–11.

    Article  PubMed  Google Scholar 

  32. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20:1989–98.

    Article  PubMed  CAS  Google Scholar 

  34. Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84:13–9.

    Article  PubMed  CAS  Google Scholar 

  35. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, et al. Effectiveness of bisphosphonate therapy in a community setting. Bone. 2009;44:153–9.

    Article  PubMed  CAS  Google Scholar 

  36. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170:765–71.

    Article  PubMed  Google Scholar 

  37. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171:998–1004.

    PubMed  Google Scholar 

  38. Khalili H, Huang ES, Jacobson BC, Camargo Jr CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344(7845):e372.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Mello M, Weideman RA, Little BB, Weideman MW, Cryer B, Brown GR. Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci. 2012;57:2416–22.

    Article  PubMed  CAS  Google Scholar 

  40. Munson JC, Wahl PM, Daniel G, Kimmel SE, Hennessy S. Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Saf. 2012;21:366–74.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23:277–84.

    Article  PubMed  CAS  Google Scholar 

  42. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24:1161–8.

    Article  PubMed  CAS  Google Scholar 

  43. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6:e17217.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women: the WHILA study. Maturitas. 2014;78:310–5.

    Article  PubMed  CAS  Google Scholar 

  45. Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res. 2014 May 13.

  46. Prieto-Alhambra D, Pagès-Castellà A, Wallace G, Javaid MK, Judge A, Nogués X, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29:268–74.

    Article  PubMed  CAS  Google Scholar 

  47. Lee J, Youn K, Choi NK, Lee JH, Kang D, Song HJ, et al. A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48:1016–22.

    Article  PubMed  CAS  Google Scholar 

  48. Abrahamsen B, Vestergaard P. Proton pump inhibitor use and fracture risk-effect modification by histamine H1 receptor blockade: observational case–control study using national prescription data. Bone. 2013;57:269–71.

    Article  PubMed  CAS  Google Scholar 

  49. Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case–control study. Ann Epidemiol. 2014;24:286–90. Another recent case control study on the association between proton pump inhibitor therapy and fracture risk of 6,774 cases and the same number of controls. A positive association was found but the highest risk was seen in those recently prescribed with no effect on those taking proton pump inhibitors for medium periods of time suggesting no dose response.

    Article  PubMed  Google Scholar 

  50. Cea Soriano L, Ruigómez A, Johansson S, García Rodríguez LA. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy. 2014;34:570–81. The most recent study evaluating the association between proton pump inhibitor therapy and risk of fracture. Evaluated 11,000 hip fracture cases and 20,000 controls from the UK Health Improvement Network. Very thoughtful study that concluded any residual association between proton pump inhibitor therapy and fracture risk was likely to be related to residual confounding.

    Article  PubMed  CAS  Google Scholar 

  51. Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int. 2014;94:597–607.

    Article  PubMed  CAS  Google Scholar 

  52. Itoh S, Sekino Y, Shinomiya K, Takeda S. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31:206–11. The only randomized controlled trial evaluating the impact of proton pump inhibitor therapy on bone mineral densityA nice trial that evaluated 180 women with low bone mineral density and randomized them into four groups in a factorial design of risedronate, rabeprazole, or placebo. As expected the bisphosphonate increased bone density but there was no significant effect of proton pump inhibitor.

    Article  PubMed  CAS  Google Scholar 

  53. Mamdani M, Sykora K, Li P, Normand SLT, Streiner DL, Austin PC, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330:960–2.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gerber Y, Melton LJ, McNallan SM, Jiang R, Weston SA, Roger VL, et al. Cardiovascular and noncardiovascular disease associations with hip fractures. Am J Med. 2013;126:169.e19–26.

    Article  Google Scholar 

  55. Ensrud KE, Ewing SK, Cawthon PM, et al. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc. 2009;57:492–8.

    Article  PubMed  PubMed Central  Google Scholar 

  56. de Vries OJ, Peeters GM, Lips P, Deeg DJ. Does frailty predict increased risk of falls and fractures? A prospective population-based study. Osteoporos Int. 2013;24:2397–403.

    Article  PubMed  Google Scholar 

  57. Leontiadis GI, Yuan Y, Howden CW. The interaction between PPIs and clopidogrel and upper gastrointestinal bleeding. Gastrointest Endosc Clin N Am. 2011;21:637–56.

    Article  PubMed  Google Scholar 

  58. Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28:154–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manage Care. 2010;16:e228–334.

    Google Scholar 

  60. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O’Fallon WM, Melton 3rd LJ. Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992;7:573–9.

    Article  PubMed  CAS  Google Scholar 

  62. Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut. 1985;26:252–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.

    Article  PubMed  Google Scholar 

  64. Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O’Brien KO, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25:2205–11.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  65. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25:2786–95.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Sharara AI, El-Halabi MM, Ghaith OA, Habib RH, Mansour NM, Malli A, et al. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2013;62:518–26.

    Article  PubMed  CAS  Google Scholar 

  67. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896–904.

    Article  PubMed  CAS  Google Scholar 

  68. Lin SC, Koo M, Tsai KW. Association between Helicobacter pylori infection and risk of osteoporosis in elderly Taiwanese women with upper gastrointestinal diseases: a retrospective patient record review. Gastroenterol Res Pract. 2014;2014:814756.

    PubMed  PubMed Central  Google Scholar 

  69. Targownik LE, Leslie WD, Davidson KS, Goltzman D, Jamal SA, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107:1361–9. An excellent study of 8,340 subjects undergoing bone mineral density testing that showed proton pump inhibitor therapy was associated with lower bone mineral density at baseline but was not associated with accelerated bone mineral loss at either 5-or 10-year follow-up.

    Article  PubMed  Google Scholar 

  70. Maggio M, Lauretani F, Ceda GP, De Vita F, Bondi G, Corsonello A, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57:437–42.

    Article  PubMed  CAS  Google Scholar 

  71. Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013;33:2255–60.

    Article  PubMed  CAS  Google Scholar 

  72. Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013;108:1094–100.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Grigorios I. Leontiadis declares no conflict of interest.

Paul Moayyedi has received speaker’s fees from AstraZeneca and his chair is partly funded by an unrestricted donation from AstraZenca to McMaster University.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, McMaster University, 1280 Main Street West, Health Sciences Center, area 3V3, Hamilton, Ontario, L8S 4K1, Canada

    Grigorios I. Leontiadis MD PhD & Paul Moayyedi BSc MB ChB PhD MPH FRCP FRCPC AGAF FACG

Authors
  1. Grigorios I. Leontiadis MD PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Moayyedi BSc MB ChB PhD MPH FRCP FRCPC AGAF FACG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Grigorios I. Leontiadis MD PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leontiadis, G.I., Moayyedi, P. Proton Pump Inhibitors and Risk of Bone Fractures. Curr Treat Options Gastro 12, 414–423 (2014). https://doi.org/10.1007/s11938-014-0030-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-014-0030-y

Keywords

Search

Navigation